Table of contents


On 22 July 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ultomiris. The marketing authorisation holder for this medicinal product is Alexion Europe SAS.

The CHMP adopted an extension to an existing indication as follows:1

Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH):

  • in patients with haemolysis with clinical symptom(s) indicative of high disease activity.
  • in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).

Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

1New text in bold

Key facts

Agency product number
International non-proprietary name (INN) or common name
  • ravulizumab
Active substance
  • ravulizumab
Therapeutic area
Hemoglobinuria, Paroxysmal
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Date opinion adopted
Company name
Alexion Europe SAS
Application type

How useful was this page?

Add your rating